Clinical trial
Post-marketing Clinical Study of Alteplase for Acute Ischemic Stroke （Japan…
NCT00412867 · Tanabe Pharma Corporation, Industry · Completed
Key facts
| NCT number | NCT00412867 |
|---|---|
| Title | Post-marketing Clinical Study of Alteplase for Acute Ischemic Stroke （Japan Alteplase Clinical Trial Ⅱ：J-ACT Ⅱ） |
| Official title | Post-marketing Clinical Study of Alteplase for Acute Ischemic Stroke (Phase 4) |
| Lead sponsor | Tanabe Pharma Corporation, Industry |
| Collaborators | Kyowa Kirin Co., Ltd. Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Stroke |
| Intervention type | Drug |
| Interventions | Alteplase |
| Enrollment | 58 |
| Start date | Dec 1, 2006 |
| Primary completion | Jun 1, 2008 |
| Completion | Jun 1, 2008 |
| First posted | Dec 19, 2006 |
| Last update posted | Jan 5, 2026 |
| Countries | Japan |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: